How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

32 results for

Sucrose Hemolysis Test

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Fluid, Electrolyte, and Nutrition Management of the Newborn (Follow-up)

or acidosis. As a result of an infant's compensatory mechanisms, blood pressure (BP) readings are usually within the reference range with mild or moderate hypovolemia. With severe hypovolemia, hypotension is almost invariably present. Laboratory evaluation Depending on the clinical situation and the suspected etiology of fluid and electrolyte derangements, some or all of the tests below may be warranted. Serum electrolyte, urea nitrogen, creatinine, and plasma osmolarity levels should be assessed. Keep (...) in mind that results of these tests, especially the creatinine levels, may still reflect maternal values over the first 12-24 hours. Serum creatinine normally declines postnatally, but very premature infants may have a delay in the decrease of serum creatinine levels. [ ] Accurate total urine output and total fluid intake may be assessed. In infants without urinary catheters or urine bags, diapers need to be weighed soon after voiding to reduce errors due to evaporation. [ ] Infants with reduced urine

2014 eMedicine Pediatrics

22. Aflunov

data, non- clinical and clinical data based on applicants’ own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or studies. Information on Paediatric requirements Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/150/2009for the following condition(s): ? Prevention of influenza on the agreement of a paediatric investigation plan (PIP) The PIP is not yet completed. Scientific advice: The applicant received (...) (MPH) involves the cultivation of the pandemic influenza virus strain in embryonated chicken eggs, harvesting of allantoic fluid, concentration by ultrafiltration and formaldehyde inactivation, followed by whole virus purification using sucrose gradient centrifugation and diafiltration. The HA and NA antigens from the surface of the purified whole virus are solubilised by treatment with a detergent (CTAB). The solubilised antigens are then separated from the non-solubilised components of the virus

2011 European Medicines Agency - EPARs

23. Vascular Disorders of the Liver

-Dacie and sucrose tests where ?ow- cytometry is unavailable Behc ¸et’s disease – Set of conventional criteria (including IVC thrombosis) Antiphospholipid syndrome – Idiopathic venous or arterial thrombosis, or repeated miscarriage – Plus, repeatedly detectable: – high serum levels of anticardiolipin antibodies – or lupus anticoagulant – or antibeta2 glycoprotein 1 antibodies (Note: In many patients low, ?uctuating levels of anticardiolipin antibodies are present. Their diagnostic value is uncertain (...) For the assessment of thrombus extension within the portal venous system, CT or MR angiography are more sensitive techniques than Doppler sonography, because the mesenteric veins are more dif?cult to visualize with ultrasound. Table 5. Tests for Prothrombotic Conditions in Patients with PVT or BCS Prothrombotic Condition Diagnostic Features Myeloproliferative disease – V617F JAK2 mutation in granulocytes is 100% speci?c. Where it is undetectable or where the technique is unavailable: – Several clusters

2009 American Association for the Study of Liver Diseases

24. Paroxysmal Nocturnal Hemoglobinuria

Nocturnal Hemoglobinuria Paroxysmal Nocturnal Hemoglobinuria Aka: Paroxysmal Nocturnal Hemoglobinuria , PNH From Related Chapters II. Pathophysiology Rare intrinsic RBC membrane defect Increased RBC sensitivity to complement damage III. Symptoms and signs Chronic Retrosternal pain Lumbar back pain Superficial migratory Nocturnal IV. Labs Test Negative Hypochromasia (Chronic urinary iron loss) Urine may be present Hemosiderin more often present or consistent with Hemosiderin s and Urine Positive (...) (Insensitive but highly specific) Increased in acid solution (Sensitive but less specific) Increased in sucrose solution V. Complications (5-10%) Thrombotic Complications Chronic VI. Management supplementation Androgen Trial for 2 months Fluoxymesterone 5-40 mg PO qd Oxymetholone 1-5 mg/kg/day PO Nandrolone decanoate 25-200 mg each week IM Dose: 0.25 - 1.0 mg/kg/day (15-40 mg PO qd) Daily steroids not recommended unless critical need Alternate day therapy may be helpful Transfusion Most patients become

2015 FP Notebook

25. Hereditary deficiency of the fifth component of complement in man. II. Biological properties of C5-deficient human serum. (PubMed)

gave normal chemotactic scores. The ability of C5D serum to opsonize Saccharomyces cerevisiae (baker's yeast) or Candida albicans for ingestion by normal neutrophils was completely normal. In addition, C5D serum was capable of promoting normal phagocytosis and intracellular killing of Staphylococcus aureus. The proband's serum was incapable of mediating lysis of erythrocytes from a patient with paroxysmal nocturnal hemoglobinuria in both the sucrose hemolysia and acid hemolysis tests, and also

Full Text available with Trip Pro

1976 Journal of Clinical Investigation

26. Biotypes of Haemophilus encountered in clinical laboratories. (PubMed)

Biotypes of Haemophilus encountered in clinical laboratories. The biochemical characteristics of 464 strains of Haemophilus influenzae and 83 strains of Haemophilus parainfluenzae isolated over an 18-month period are described. Of 22 characteristics obtained, only 6 were necessary to biochemically identify and biotype the isolates. The key substrates or tests were urease, ornithine, indole, o-nitrophenyl-beta-D-galactopyranoside, sucrose, and xylose. Five biotypes of H. influenzae and four of H (...) and from those over 20 years of age. Multiple isolates recovered from the same patient were almost always of the same biotype. Strains of H. parainfluenzae were isolated primarily from sputum, with others being isolated from body sources such as dental abscesses, gastric aspirates, and peritoneal fluid. An inverse relationship was noticed between hemolysis and mannose fermentation among H. parainfluenzae biotype III strains, whereas the relationship was absent among the other biotypes.

Full Text available with Trip Pro

1979 Journal of clinical microbiology

27. Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics

the inactivation period. The inactivation cycle depends upon the characteristics of specific virus strains. The inactivation temperature is selected in order not to compromise antigenicity. Purification The virus is removed from the inactivated allantoic fluid using continuous flow isopycnic ultracentrifugation and a sucrose density gradient, which concentrates and purifies the virus. The different fractions which contain the purified virus are collected and tested. The fractions are pooled together (...) quality data, non- clinical and clinical data based on applicants’ own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or studies. Information on Paediatric requirements Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/150/2009for the following condition(s): ? Prevention of influenza on the agreement of a paediatric investigation plan (PIP) The PIP is not yet completed. Scientific advice: The applicant received

2010 European Medicines Agency - EPARs

28. Paroxysmal Nocturnal Hemoglobinuria (PNH)

and are discussed elsewhere in The Manual. Diagnosis Flow cytometry PNH is suspected in patients who have typical symptoms of anemia (eg, pallor, fatigue, dizziness, possible hypotension) or unexplained normocytic anemia with intravascular hemolysis, particularly if leukopenia or thrombocytopenia and/or thrombotic events are present. Historically, if PNH was suspected, the acid hemolysis (Ham test) or sugar-water test was usually the first test done. These tests relied on activation of complement via (...) acidification of serum or high-concentration sucrose solutions. Currently, diagnosis of PNH is with flow cytometry, which is used to determine the absence of specific RBC or WBC cell surface proteins (CD59 and CD55) . This test is highly sensitive and specific. Bone marrow examination is not necessary but, if done to exclude other disorders, usually shows erythroid hyperplasia. Gross hemoglobinuria is common during crises, and the urine may contain hemosiderin. Treatment Supportive measures Eculizumab

2013 Merck Manual (19th Edition)

29. Paroxysmal nocturnal hemoglobinuria

counts may be seen at this. In this case, anemia may be caused by insufficient red blood cell production in addition to the hemolysis. Historically, the sucrose lysis test, in which a patient's red blood cells are placed in low-ionic-strength solution and observed for hemolysis, was used for screening. If this was positive, the (after Dr Thomas Ham, who described the test in 1937) was performed for confirmation. The Ham test involves placing red blood cells in mild acid; a positive result (increased (...) to the presence of defective surface protein on the , which normally functions to inhibit such immune reactions. Since the complement cascade attacks the red blood cells within the blood vessels of the , the red blood cell destruction (hemolysis) is considered an intravascular hemolytic anemia. Other key features of the disease, such as the high incidence of , are incompletely understood. PNH is the only hemolytic anemia caused by an acquired (rather than inherited) intrinsic defect in the (deficiency

Full Text available with Trip Pro

2012 Wikipedia

30. Celvapan - influenza vaccine (H1N1)v

in the Monovalent Bulk; Vero Host Cell Protein; residuals of formaldeyde, sucrose, trypsin and benzonase. The agreed specifications for the monovalent bulk include a test for vero cell protein via ELISA, the Haemagglutinin assay and SRD test for HA protein, the Bradford Method for total protein, the Haemagglutination Inhibition test, H5N1 identity test using RT PCR, a safety test for preparative influenza virus on Vero cells, a test for Tween 80 concentration via photometric detection, the LAL test (...) to determine total protein, a PCR test for detection of residual Vero cell DNA, an ELISA test for residual benzonase as well as tests for Tween 80 concentration, sucrose, formaldehyde, ph and sterility. Quality control testing performed on Final Container Product consists of SRH Assay for quantification of haemagglutinin (HA), extractable volume, ph, bacterial endotoxin using the LAL test and sterility. All analytical methods are performed according to Ph. Eur. where applicable and are validated according

2009 European Medicines Agency - EPARs

31. Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer

Adult Solid Tumor, Protocol Specific Biological: darbepoetin alfa Dietary Supplement: ferrous sulfate Drug: sodium ferric gluconate complex in sucrose Other: placebo Phase 3 Detailed Description: OBJECTIVES: Primary * To compare the effects of IV iron, oral iron, or placebo in combination with darbepoetin alfa on the hematopoietic response rate, defined as a hemoglobin increment of ≥ 2.0 g/dL from baseline or achievement of hemoglobin of ≥ 11 g/dL in the absence of red blood cell transfusions (RBC (...) darbepoetin alfa subcutaneously and sodium ferric gluconate complex IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity. Biological: darbepoetin alfa Given by injection Drug: sodium ferric gluconate complex in sucrose Given by IV Experimental: Arm II Patients receive darbepoetin alfa as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity

2008 Clinical Trials

32. Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases

: Sustained reticulocytosis (greater than 125,000/mm3) without evidence of active bleeding or increasing hemoglobin Laboratory evidence of hemolysis Positive direct antiglobulin test or equivalent immune adherence test No evidence for paroxysmal nocturnal hemoglobinuria Negative Ham's test and sucrose hemolysis. For PRCA: Anemia due to selective decrease in marrow erythroid precursors Hemoglobin less than 10.0 g/dL without transfusion Severe reticulocytopenia (less than 20,000/mm3 despite anemia) Severely (...) decreased marrow erythroid precursors Positive marrow coculture with serum or cells or response to immunosuppression No evidence for PNH Negative Ham's test and sucrose hemolysis Severe disease: Chronic (i.e., greater than 1 year) Transfusion dependent or untransfused hemoglobin less than 8.0 g/dL Ferritin greater than 2,000 or evidence of organ dysfunction due to iron overload Refractory to conventional therapy after all 3 of the following: High dose steroids (at least 1 mg/kg) for at least 21 days

2000 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>